Do drug funding decisions need PR? A response

healthydebate.ca- This is in response to the article “Do drug funding decisions need pr?” Read the full article here.

Mark this case a clear FAIL. Health Canada and related agencies abdicated their responsibility to properly inform the public and allowed industry to manipulate and poison the biosimilar conversation. Physicians were pressured to stamp all of their biologic prescriptions with a Do Not Substitute order. Prestigious physicians wrote opinion articles disguised as evidence-based reporting that were published in medical journals advocating against substitution. And patient organizations, whether knowingly or not were parties to delivering mixed messages to patients by disseminating material and webinars produced and paid for by drug companies.

Worse still, its been reported that coercive marketing tactics by originators took advantage of many patients’ vulnerability while they were in hospital that directly interfered in and biased their treatment, resulting in the loss of their biologically naïve status and their right to choose a therapy most appropriate for them.

However, the Holy Grail of scientific evidence, such as The NOR-SWITCH Study, is now proving that biosimilars are equally effective in patients who switch.

So at this late stage of the conversation should regulators step in with a communications plan? It’s clear that fighting a [...] continue the story